1. Introduction {#sec0001}
===============

Frontal alpha asymmetry (FAA) is a proposed biomarker conventionally acquired with electroencephalography (EEG). FAA has been studied for over three decades in major depressive disorder (MDD), anxiety, and other psychiatric diseases. Several studies stated, in a traditional framework of FAA, that it reflects the approach-withdrawal motivation system, i.e. the diathesis model ([@bib0009]; [@bib0020]; [@bib0021]; [@bib0024]). Left-sided FAA (i.e. more right-sided frontal cortical activation than left-sided) was correlated more to withdrawal behavior than to approach, which was in turn associated with a vulnerability to developing MDD. However, our meta-analysis showed that FAA cannot be used as a generic diagnostic biomarker in MDD and does not reliably differentiate MDD from non-MDD patients ([@bib0040]), providing evidence against the diathesis model. Only a small subgroup of severely depressed females over 53 years of age showed more right-sided alpha activity and severely depressed males over 53 years of age more left-sided alpha than control peers.

When regarding FAA as a *prognostic* rather than *diagnostic* biomarker, alpha asymmetry may be more promising. Bruder and colleagues (2008) found SSRIs (selective serotonin reuptake inhibitors) treatment responders to have more right-sided alpha asymmetry while non-responders showed opposite asymmetry, primarily over the occipital region. This was confirmed in the large international Study for Predicting Optimized Treatment -- Depression sample, where specifically female SSRI responders had more right-sided FAA, and non-responders the opposite (iSPOT-D, [@bib0002]). To further assess properties of FAA as a prognostic biomarker, knowledge on its reliability, stability, and sensitivity to other factors, such as medication or severity of depression, needs to be established.

A predominant view in affective neuroscience is that FAA in depressed patients consists of mostly *trait*-like features, not changing over time with *state* and independent of interventions, although some studies have suggested otherwise: both longitudinal and cross-sectional designs have been used to test FAA stability (see [Table 1](#tbl0001){ref-type="table"} for a summary, and appendix [Table A1](#tbl0003){ref-type="table"} for a detailed overview of studies). With an exception of [@bib0011], most studies report FAA to be stable with minor or no changes between baseline and assessment later, both in patients and healthy controls ([@bib0001]; [@bib0005]; [@bib0010]; [@bib0012]; [@bib0014]; [@bib0025]; [@bib0034]; [@bib0036]; [@bib0038]).Table 1Summary of studies on state/trait properties of frontal alpha asymmetry.Table 1StudyStudy type[\*](#tb1fn1){ref-type="table-fn"}Mostly traitNot trait - or mostly stateSubjectsEEG methodsIntervention[@bib0001]1XMDD, female3 to 5 Ax., 8 or 16 weeks apartAcupuncture[@bib0005]1XMDD and HC2 Ax., 12 weeks apartFluoxetine treatment[@bib0011]1XMDD and HC2 Ax., 2--4 weeks apartSeveral antidepressants[@bib0012]1XMDD and HC4 Ax. On 1 dayCognitive restructuring[@bib0014]1XMDD and HC2 Ax., 16 weeks apartBehavioral activation[@bib0025]1XMDD2 Ax., 8 weeks apartMindfulness[@bib0034]1XMDD2 Ax., pre/post-treatmentrTMS[@bib0041]1XChildhood onset MDD and HC2 Ax., 1--3.2 years apartSome patients on ADs (13 of *n* = 49)[@bib0010]2X[⁎⁎](#tb1fn2){ref-type="table-fn"}HC3 Ax., 8 weeks, 4 monthsMindfulness meditation[@bib0019]2XHC4 Ax., all 4 weeks apartNone[@bib0018]2XXHC3 Ax., all 5 weeks apartNone[@bib0036]2XHC2 Ax., 6 weeks apartNone[@bib0037]2XXHC2 Ax., 5--16 days apartNone[@bib0038]2XHC2 Ax., 3 weeks apartNone[@bib0007]3X[⁎⁎](#tb1fn2){ref-type="table-fn"}MDD, remitted, and HC1 Ax.None[@bib0013]3X[⁎⁎](#tb1fn2){ref-type="table-fn"}MDD, remitted, and HC1 Ax.None[@bib0015]3XMDD, remitted, and HC1 Ax.None[@bib0017]3X[⁎⁎](#tb1fn2){ref-type="table-fn"}MDD and HC1 Ax.None[@bib0028]3XMDD and HC1 Ax.None[^1][^2][^3]

Cross-sectionally, several studies showed that FAA is independent of depression severity, both between patients ([@bib0001]; [@bib0002]; [@bib0013]; [@bib0014]; [@bib0028]; [@bib0040]; [@bib0041]) and within patients, including remission ([@bib0007]). This contrasts the findings by [@bib0017] and [@bib0001], where a higher level of depression complaints correlated with more left-sided FAA (albeit only in the control group of Grünewald et al.). In other cross-sectional studies on FAA stability between depressed patients and patients remitted from depression, no differences were found ([@bib0007]; [@bib0013]; [@bib0015]).

Despite some inconclusive results, the majority of findings indicate that FAA is predominantly a trait, only partially or not affected by changes in depressive state. Our meta-analysis on FAA as a diagnostic marker of depression ([@bib0040]) demonstrated that bias is strongly reduced from 300 cases onwards. Studies investigating FAA stability until now always studied smaller samples (*n* ≤ 85). This may explain part of the conflicting results on FAA in these studies.

This has motivated our current work that aims to replicate longitudinal results on the temporal stability of FAA by using data from the iSPOT-D dataset (baseline *n* = 1008, week-8 *n* = 453). The primary hypothesis was that FAA is reliable, and remains stable over time, with limited changes as a result of antidepressant treatment, time and state change. We therefore assessed FAA after eight weeks of antidepressant drugs and consequential state changes in mood. As age, sex, and depression severity have had a significant influence on FAA-related outcomes in iSPOT-D and other studies (e.g. [@bib0002]; [@bib0006]; [@bib0035]; [@bib0040]), we extended analyses by investigating possible mediation of FAA by these variables. We specifically studied MDD patients versus healthy controls differentiating subgroups identified in our previous meta-analysis, i.e. severely depressed patients over 53 years old ([@bib0040]). As in earlier iSPOT-D reports on FAA anxiety was not found to be of influence, we did not add this variable to our analyses.

For clinical use of FAA as a biomarker for treatment response, it is relevant to assess stability and robustness to medication. Stability is particularly an advantage when patients are already on an AD preceding baseline (that often have long half-life times requiring wash-out periods of weeks) and FAA remains unaffected. We therefore also assess outcome prediction with FAA recorded after eight weeks treatment. In our previous report ([@bib0002]), at baseline, right-sided FAA in females was associated with favorable outcome to the SSRIs escitalopram and sertraline, whereas left-sided FAA was not. If FAA *is* prognostic for AD treatment outcome in specific subsamples, and FAA is indeed a stable *trait*, FAA after eight weeks on an AD should still be able to predict treatment outcome for females in agreement with our previous study ([@bib0002]). We hypothesized that analysis of week-8 medicated EEG data would result in the same treatment prediction results as baseline unmedicated data did.

2. Materials and methods {#sec0002}
========================

2.1. Design {#sec0003}
-----------

This is an international multi-center, randomized, prospective open-label trial (Phase-IV clinical trial), in which MDD patients were randomized to escitalopram, sertraline, or venlafaxine-XR treatment in a 1:1:1 ratio. The study protocol details, including a power calculation, have been published by [@bib0042]. This design was deliberately chosen to mimic real-world practice with the aim of optimizing the translatability to real world settings.

2.2. MDD patients and treatment {#sec0004}
-------------------------------

We included 1008 MDD patients, recruited between October 2008 and January 2011. A detailed description of the study assessments, inclusion/exclusion criteria, diagnostic procedures and treatment is available in [@bib0042]. In summary, the primary diagnosis of nonpsychotic MDD was confirmed before randomization using the Mini-International Neuropsychiatric Interview (MINI-Plus, [@bib0033]), according to DSM-IV criteria, and a score ≥16 on the 17-item Hamilton Rating Scale for Depression (HRSD~17~). Additional measuring of depression complaints was done with the Very Quick Inventory of Depressive Symptomatology -- Self Report (VQIDS-SR~5~, [@bib0027]). Comorbid anxiety disorders were allowed (present in 6.2% \[specific phobia\] to 10.5% \[social phobia\] of patients). All patients were either medication-naive or, if previously prescribed an antidepressant medication, had undergone a washout period of at least five half-lives before the baseline visit clinical and EEG assessments. After the baseline visit, patients were randomized to one of three antidepressant medication treatments. After eight weeks of treatment, patients were tested again using the HRSD~17~, the VQIDS-SR~5~ and an EEG assessment ([Fig. 1](#fig0001){ref-type="fig"}). This study was approved by the institutional review boards at all of the participating sites and this trial was registered with ClinicalTrials.gov. Registration number: NCT00693849; URL: http://clinicaltrials.gov/ct2/show/NCT00693849.Fig 1Consort diagram of the iSPOT-D study. *Abbreviations*: ADHD, attention deficit hyperactivity disorder; AD, antidepressant treatment; HRSD~17~, 17-item Hamilton rating scale for depression; MDD, major depressive disorder; PTSD, post-traumatic stress disorder; XR, extended release.Fig 1

2.3. Pre-treatment assessments {#sec0005}
------------------------------

EEG recordings were performed using a standardized methodology and platform (Brain Resource Ltd., Australia). Details of this procedure ([@bib0003]; [@bib0042]) and of its reliability and across-site consistency have been published elsewhere ([@bib0029]; [@bib0043]). In summary, subjects were seated in a sound and light attenuated room that was controlled at an ambient temperature of 22 °C. EEG data were acquired from 26 channels: Fp1, Fp2, F7, F3, Fz, F4, F8, FC3, FCz, FC4, T3, C3, Cz, C4, T4, CP3, CPz, CP4, T5, P3, Pz, P4, T6, O1, Oz and O2 (Quik-cap; NuAmps; 10--20 electrode international system). EEG was assessed for two minutes with eyes open (EO) (with the subject asked to fixate on a red dot on the screen) and two minutes with eyes closed (EC). The subject was instructed to remain relaxed for the duration of the recording. The operator did not intervene when drowsiness patterns were observed in the EEG. Data were referenced to averaged mastoids with a ground at AFz. Horizontal eye movements were recorded with electrodes placed 1.5 cm lateral to the outer canthus of each eye. Vertical eye movements were recorded with electrodes placed 3 mm above the middle of the left eyebrow and 1.5 cm below the middle of the left bottom eyelid. Skin resistance was \<5 K Ohms for all electrodes. The sampling rate of all channels was 500 Hz. A low pass filter with an attenuation of 40 dB per decade above 100 Hz was employed prior to digitization.

2.4. EEG analysis {#sec0006}
-----------------

A detailed overview of the data-analysis can be found in [@bib0002]. In summary, data were (1) filtered (0.3--100 Hz and notch); (2) EOG-corrected using a regression-based technique similar to that used by [@bib0016], segmented in 4-second epochs (50% overlapping), and an automatic de-artifacting method was applied. This EEG processing pipeline was also validated against an independent manual-processing pipeline ([@bib0002]). For further analysis, an average reference was applied, data were filtered (alpha power (µV^2^): 8--13 Hz) and FAA was calculated between F3 and F4 as (F4 -- F3)/(F4 + F3).

2.5. Statistics {#sec0007}
---------------

Normal distribution was inspected, and appropriate transformations performed in case of non-normality. Non-log transformed alpha power was used to calculate FAA. Remission was defined as a score ≤7 on the HRSD~17~ eight weeks after starting treatment (current endpoint), and response was defined as *a* ≥ 50% decrease in HRSD~17~ score from baseline to eight weeks. To control for antidepressant side-effects, we employed the VQIDS-SR~5~, developed specifically to focus on the core symptoms of depression. This enabled us to measure true depression severity, ruling out antidepressant side-effects such as physical complaints. We repeated ANOVAs from paragraph 3.2 and 3.3 and replaced all HRSD~17~ variables with VQIDS-SR~5~ equivalents. Results are reported in [Appendix D](#sec0018){ref-type="sec"}.

Differences in age, sex, education, and depression severity at baseline were tested using one-way ANOVA or non-parametric tests, depending on its distribution. We only included patients who returned for their week-8 visit while on their assigned medication, having followed this treatment for a minimum of 6 weeks ('per-protocol' grouping, also see the Consort diagram in [Fig. 1](#fig0001){ref-type="fig"}).

FAA reliability analysis was performed by calculating Intraclass Correlations (ICCs) across baseline and week-8 measurements. A full-factorial Repeated Measures ANOVA was conducted with the within--subject factor FAA Change Eyes Closed (FAA at baseline and after eight weeks) and between-subject factor Treatment arm (comparing drug effects of respectively escitalopram, sertraline, and venlafaxine). Given the large sample size we set the significance level for main effects found for FAA Change in the main analyses at *p* ≤ .01, for interaction effects this remained at a conventional level of *p* ≤ .05. When significant interactions were found prompting subgroup analyses, again a level of *p* ≤ .05 was used. Effect sizes (ES) of main effects are reported in Cohen\'s *d*. FAA stability was also tested through Pearson correlations between FAA Change and HRSD~17~ Change.

Post hoc, we repeated the Repeated Measures and Pearson correlations analyses in the subgroups of moderately and severely depressed (HRSD~17~ score of ≥24) over the age of 53, separately for males and females (conform our meta-analysis, [@bib0040]). However, as these groups might lead to underpowered tests, we also performed a custom Repeated Measures ANCOVA on the whole dataset, now also including covariates Age and Depression severity, separately for males and females.

When a null hypothesis was not rejected by any of the ANOVAs or correlational analyses, we utilized Bayesian alternatives. This was done for testing evidence of *absence* of a change in FAA, using the Bayesian Repeated Measures ANOVA framework (based on work by [@bib0023] and [@bib0030]). We analyzed the data with JASP ([@bib0022]). The first null hypotheses states that there is no difference in FAA between baseline and after 8 weeks. The second that FAA Change is not correlated to HRSD~17~ Change. The two-sided alternative hypotheses state that FAA changed after eight weeks, or that FAA is correlated to HRSD~17~ Change.

Through a Repeated Measures model ([@bib0002]), we again predicted treatment outcome in females taking an SSRI (escitalopram or sertraline), while this time replacing baseline FAA with week-8 FAA (within subjects variable FAA Condition (EC and EO), and between subjects variable Response, and covariate Age). We tested effects one-tailed (halved *p*-values were reported) because we specifically expected more right-sided FAA in SSRI responders than in non-responders, implying that a result in the unexpected direction would lead to the same conclusion as finding no differences at all ([@bib0031]). In [Appendix B](#sec0016){ref-type="sec"}, we explain why we compare the smaller sample containing only patients who were present for the assessment after 8 weeks, to the larger sample with *all* baseline patients from the previous study.

3. Results {#sec0008}
==========

Of the 1008 MDD patients enrolled, the final MDD sample for the FAA Change analyses consisted of 453 MDD patients. The remaining 555 patients were left out of the study: they either never started treatment, had less than 6 weeks of medication, or had no week-8 assessment (or it was of insufficient quality) (see [Fig. 1](#fig0001){ref-type="fig"}). [Table 2](#tbl0002){ref-type="table"} shows demographic information and response and remission rates for included patients. There were no differences between the three treatment groups regarding age, sex, baseline MDD, anxiety severity, remission and response rates, or number of rejected EEG epochs. Approximately 5.3% of EEG epochs were rejected due to artifacts for the MDD group during EC.Table 2Demographic features and treatment outcomes for patients who completed treatment.Table 2EscitalopramSertralineVenlafaxine-XRTotalN136169148453Females719680247% Female52.556.854.154.5Average age (years)38.2738.7237.9838.34HRSD~17~ baseline21.4521.7421.4521.56HRSD~17~ week-88.629.259.018.98VQIDS-SR~5~ baseline8.018.347.998.13VQIDS-SR~5~ week-83.263.353.213.28% Remission (HRSD~17~)51.546.744.647.5% Response (HRSD~17~)66.266.966.266.4

3.2. FAA change over time {#sec0009}
-------------------------

ICCs for FAA with both continuous and dichotomous (leftward or rightward FAA) variables were 0.276 and 0.256, respectively. The Repeated Measures ANOVA revealed no evidence for change in FAA after AD treatment (*F*(1,450) = 1.421, *p* = .234), nor an interaction with Treatment Arm (*F*(2,450) = 0.690, *p* = .502). FAA Change was neither significantly correlated to the change score in HRSD~17~ (*r* = 0.039, *p* = .410), nor to the percentage change in HRSD~17~ (*r* = 0.047, *p* = .323).

Results of Bayesian Repeated Measures testing of invariant (constant) FAA revealed a Bayes factor indicating evidence for the null hypothesis. The models with the factors FAA Change and Treatment Arm showed that the data occur \>7.4 times more likely under the null hypothesis, than under any alternative model with (a combination of) the factors. Bayesian Pearson correlations between FAA Change and the difference score HRSD~17~/the percentage difference of HRSD~17~ reveal moderate to strong results. The data are respectively 12.1 and 9.3 times more likely to occur under the null hypothesis than under the model assuming a correlation between the variables. See [Appendix F](#sec0020){ref-type="sec"} for an elaboration on results and JASP tables.

3.3. Extended repeated measures model and correlations {#sec0010}
------------------------------------------------------

Focusing on variables known to have an influence on FAA, specifically in the subgroup we thought to be prone to changes in FAA (severely depressed females and males over 53 years old), we did not find significant changes, although subsample sizes were small. Furthermore, in these subgroups the FAA Change score was not significantly correlated to the change score in HRSD~17~ (see appendix [Table C1](#tbl0005){ref-type="table"} for all statistics). Bayesian Repeated Measures ANOVAs for the two sex groups of severely depressed over the age of 53 reveal anecdotal (i.e. worth no more than a bare mention, a customary description for BFs ranging 1--3) to moderate results. Most models therefore provided no conclusive evidence for either the null or the alternative hypotheses, although some models indicated moderate evidence of the data being more likely to occur under the null hypothesis. See [Appendix F](#sec0020){ref-type="sec"} for an elaboration on results and JASP tables.

Extending the Repeated Measures model from paragraph 3.2 showed that - irrespective of sex - baseline severity and age are not significantly contributing to FAA Change. Bayesian Repeated Measures alternatives for the extended ANOVAs showed similar results to paragraph 3.2. For females, the data are ≥6.6 times more likely to occur under the null hypothesis, than under any alternative model with (a combination of) the factors, and ≥4.7 times more likely in case of males. See [Appendix F](#sec0020){ref-type="sec"} for an elaboration on results and JASP tables.

3.4. Treatment prediction using medicated week-8 data in females {#sec0011}
----------------------------------------------------------------

Treatment outcome prediction with week-8 data, revealed a similar prediction pattern as baseline data reported in [@bib0002]: one-tailed testing of the prediction of response in females taking an SSRI for depression (escitalopram or sertraline), treatment response effects remained significant with week-8 FAA on group level (*F*(1,150) = 3.725, *p* = .028). Furthermore, the response effect of FAA was again lacking after eight weeks in the venlafaxine group.

The week-8 SSRI data in [Fig. 2](#fig0002){ref-type="fig"} visualize how responders were significantly more right-sided than non-responders (based on female FAA means reported in appendix [Table E1](#tbl0007){ref-type="table"}). [Fig. 2](#fig0002){ref-type="fig"} also shows how the response effect was similar to the baseline assessment. This was despite the confidence interval (CI) of FAA in [Fig. 2](#fig0002){ref-type="fig"} (SSRI non-responders) showing no significant difference from 0 when measured with EO after eight weeks. No interactions with age were observed. The equivalent of [Fig. 2](#fig0002){ref-type="fig"} data for males is available in Appendix G.Fig 2Mean values of female frontal alpha asymmetry (FAA, eyes open and eyes closed \[EO and EC\]), for the SSRI and venlafaxine groups, split up for responders and non-responders. Error bars represent standard error of the mean. The means and error bars indicate that baseline and week-8 FAA were not significantly different in predicting treatment outcome in females; SSRI responders showed right-sided, non-responders left-sided FAA. No differences were, yet again, observed for the venlafaxine group. The equivalent of this data for males is available in Appendix G.Fig 2

Cohen\'s *d* comparing FAA change scores of female SSRI responders and non-responders was 0.304. When using the direction of week-8 FAA alone to prescribe an SSRI or SNRI would have improved the overall remission rate from 47% to 56--58% for an SSRI.

4. Discussion {#sec0012}
=============

We investigated the stability of FAA in MDD patients during antidepressant treatment. We hypothesized that FAA is a robust metric, insensitive to time, antidepressant drug treatment and state changes. FAA did not change significantly after eight weeks of escitalopram, sertraline, or venlafaxine treatment, despite a relatively low reliability of the FAA measurements. Additional Bayesian testing revealed that a stable FAA is more likely than a change in FAA over time after antidepressant treatment. Furthermore, post-hoc tests with variables known to have influence on FAA (in earlier iSPOT-D studies), revealed no differential temporal changes in FAA in depressed patients differing on age, sex, depression severity, or change in depression severity. Focusing on core depression symptoms only (as measured by the VQIDS-SR~5~, see [appendix D](#sec0018){ref-type="sec"}), we found similar results.

To further confirm FAA temporal stability, we hypothesized that predicting treatment outcome in females taking SSRIs would lead to similar outcome when using *week-8* FAA instead of the previously studied *baseline* FAA ([@bib0002]). This re-analysis indeed confirmed an overall response in the SSRI group with right-sided FAA, and a non-response with left-sided FAA. Although the effect size was less pronounced with week-8 data, week-8 FAA yielded the same conclusions as the baseline measurements, with a Cohen\'s *d* of 0.547 in the previous analyses vs. our current 0.304. Furthermore, we yielded the same improvement in remission rates when week-8 FAA had been used for 'prescribing' medication: previous SSRI remission rates improved from 46% to 53--60% using baseline FAA, the current from 47% to 56--58% using week-8 FAA. This extends the use of FAA as a prognostic biomarker, as response prediction was neither modified by moment of assessment, nor by AD treatment.

The low reliability was unexpected, and implies that FAA following treatment was not as stable as in previous studies. In several studies, FAA was found to be relatively reliable and consistent, based on ICCs and Cronbach\'s alpha ([@bib0001]; [@bib0011]; [@bib0025]; [@bib0036]; [@bib0039]). Especially [@bib0039] demonstrated FAA consistency, through several methods. An important difference is the use of a single FAA statistic per assessment time (two in total) in our study vs. several other studies using (fictive) multiple time points. This could account for our lower reliability. Despite the low ICC, we did replicate no evidence for a significant change in FAA over time, in a large sample (*N* = 453).

To our knowledge, this is the first study to assess the temporal stability of FAA in a large sample. This supports previous studies showing that FAA mainly depends on a considerable number of trait-like features, insensitive to antidepressant treatment, age, sex or depression severity ([@bib0001]; [@bib0002]; [@bib0005]; [@bib0007]; [@bib0012]; [@bib0013]; [@bib0014]; [@bib0025]; [@bib0028]; [@bib0034]; [@bib0036]; [@bib0038]; [@bib0040]; [@bib0041]). Similarly, [@bib0032] showed no evidence for antidepressant elicited changes in FAA when comparing a small group of depressed patients on ADs with unmedicated patients. In other small cohorts, FAA was not modified by the use of antidepressive medication either ([@bib0005]; [@bib0041]), in agreement with our observations.

In the prevailing approach-withdrawal motivation system hypothesis, it is assumed that FAA is associated with lifetime MDD (having had at least one depressive episode in one\'s life), and not specifically current MDD. This is an important distinction, and our results initially support this theory. The motivation system hypothesis states that FAA is not expected to change as a result of changes in MDD status, and ultimately not with MDD remission. However, with establishing FAA (in)stability, our study would neither provide evidence for, nor against the theory. That is, if we would have found the opposite result (a change in FAA), this could have been explained as well, by the related capability model ([@bib0008]). This model states that resting state FAA is more prone to fluctuations than FAA measured after inducing positive or negative mood. Because we measured resting state FAA, either outcome could be explained within the approach-withdrawal motivation system, given the capability model. Therefore, it is difficult to unambiguously place our results in the existing theories. Note that our earlier findings were less compatible with the motivation system: Firstly, in the approach-withdrawal motivation system, left-sided FAA is theorized to be more associated with withdrawal behavior and depression. But brain asymmetry was found not to be different in these groups as measured both through EEG FAA ([@bib0040]), and through fMRI in a recent large ENIGMA consortium study ([@bib0026]). Secondly, prognostic results for females in the FAA iSPOT-D study ([@bib0002]) revealed heterogeneity in MDD patients, not consistent with assuming a homogenic FAA related vulnerability for MDD. In sum, the current study was not designed to directly investigate the approach-withdrawal motivation theory, and cannot provide support in favor of or against the theory.

We show that FAA is a robust metric, suitable for sex specific treatment prediction under challenging circumstances, such as state, time, the use of common antidepressive agents and drug changes. This suggests reliable implementation in clinical practice as a prognostic biomarker in both medicated and unmedicated patients.

5. Conclusions {#sec0013}
==============

In an adequately powered sample, we demonstrate that (1) neither antidepressant medication, (2) nor MDD state and severity, have systematic effects on FAA. This confirms FAA stability. Furthermore, as prognosis of treatment response is irrespective of the moment of measurement, FAA may serve as a robust biomarker to optimize MDD treatments.

Appendix A {#sec0015}
==========

[Table A1](#tbl0003){ref-type="table"}.Table A1Overview of FAA stability related studies.Table A1StudyStudy type\**N*=SubjectsEEG MethodsInterventionRelevant factors[@bib0001]130MDD (females)3 to 5 Ax., 8 or 16 weeks apartAcupuncture (specific and non-specific)HRSD change score[@bib0005]118MDD and HC2 Ax., 12 weeks apartFluoxetine treatmentResponse ("CGI-I rating much or very much improved")[@bib0011]115 and 22MDD and HC2 Ax., 2--4 weeks apartSeveral antidepressantsBDI-score[@bib0012]115 and 18MDD and HC4 Ax. On 1 dayCognitive restructuringHappiness change score[@bib0014]137 and 35MDD and HC2 Ax., 16 weeks apartBehavioral activationIDS-SR[@bib0025]178MDD2 Ax., 8 weeks apart (neutral vs. sad state)MindfulnessBDI en BDI-Change, gender[@bib0034]18MDD2 Ax., pre/post-treatmentrTMSNone that was associated with frontal asymmetry[@bib0041]149 and 50Childhood onset depression and HC2 Ax., 1--3.2 years apartSome cases on ADs (13 of *n* = 49)Age, sex, BDI[@bib0010]241HC2 Ax., 8 weeks, 4 monthsMindfulness meditation[@bib0019]259HC4 Ax., all 4 weeks apartNone[@bib0018]259HC3 Ax., all 5 weeks apartNone[@bib0036]246HC2 Ax., 6 weeks apartNoneNo depression scores (only BIS/BAS and PANAS)[@bib0037]239HC2 Ax., 5--16 days apartNone[@bib0038]285HC2 Ax., 3 weeks apartNone[@bib0007]312, 8 and 7MDD, remitted and HC1 Ax.NoneBDI[@bib0013]322, 16 and 34MDD, remitted and HC (also other groups, with comorbid anxiety)1 Ax.NoneBDI[@bib0015]316, 31 and 30MDD, remitted and HC1 Ax.None[@bib0017]328 and 31MDD and HC1 Ax.NoneBDI[@bib0028]337 and 69MDD and HC1 Ax.NoneBDIStudyRelevant analysesCalculation FAAConclusion[@bib0001]FAA solely: ICCs. FAA in relation to symptoms: Correlations & multivariate Repeated Measures analysis of variance (HRSD-score) with changing covariates (3 asymmetry measures)ln\[Right\] - ln\[Left\]Stable across time and independent of depression severity.[@bib0005]1. Interaction Response-Nonresponse-HC \* Hemisphere \* Site. 2. Interaction Response \* Site \* Hemisphere \* Session. 3. Test-retest correlations.Interaction of site and hemisphereOverall stable. 1. No FAA differences between groups. 2. No change of FAA over time. 3. Moderate test-rest correlations of FAA after treatment.[@bib0011]1. Cronbachs alpha FAA for internal consistency. 2. Correlation FAA-BDI. 3. Temporal stability through Pearson correlations.1. Interaction of session \* site \* region (posterior-anterior) \* Hemisphere 2. ln(right) - ln(left)Overall: Not a stable measure. 1. Good internal consistency. 2. No correlation with BDI, so state-independent. 3. Unstable temporal stability of frontal regions (not posterior).[@bib0012]1. Interaction Diagnosis \* Block \* Region \* Laterality 2. Correlation FAA-Happiness score1. Interaction with region and laterality 2. ln F4 - ln F3Overall: no changes between assessments on the same day. 2. No correlation.[@bib0014]1. Rep Measures ANOVA FAA over time. 2. Correlation pre FAA-pre IDS/pre FAA-post IDS/post FAA-pre IDS/post FAA-post IDSlog F4 - log F3Overall: FAA = stable, trait-like. 1.No changes in FAA. 2. No significant correlations.[@bib0025]1. Cronbachs alpha. 2. ANOVA interaction FAA time 1 \* time 2. 3. Correlation FAA-affect scores (to test state). 4. Test-retest reliability with Pearson product moment correlations. 5. Correlation FAA-BDI time 1. 6. Correlation FAA Change-BDI Change. 7. Interactions with gendersubtracting power values in the left hemisphere from the values in the right hemisphere1. Stable. 2. Change (in sad condition, not in neutral). 3. No correlation with affect, so stable. 4. Correlates, so reliable. 5. Significant correlation FAA-BDI in sad condition (not in neutral, this was only for other sites). 6. No correlation. 7. No gender interaction effects.[@bib0034]Interaction of Time \* Hemisphere (left: F3, FC3, F7. Right: F4, FC4, F8)Interaction of time and hemisphereNo interaction for alpha1, alpha2 and alpha. Alpha seems a trait.[@bib0041]1. Cronbach\'s alpha. 2. ANOVA with Age, apart for the sexes. 3. ICC 4. ANOVA with group, sex, and FAA at Time 2 as dependent variable, on Time 1 as dependent variable. 5. Same analyses, apart for with and without medication. 6. Regression on FAA Time 2, with FAA Time 1, BDI and BDI-change.ln(F4) - ln(F3)Overall: Moderate to high long term stability. 1. Consistent. 2. No influence of Age or Sex. 3. Moderately stable. 4. Stable after p-value correction, without correction there would be differences. 5. Same results with and without medication, so stable. 6. Depressive symptom severity and change in symptoms did not affect EEG asymmetry stability.[@bib0010]Group (mindfulness/waitlist) \* Time.ln(F4) -- ln(F3), ln(F8) -- ln(F7)Changes in asymmetry were only observed in other electrode pairs, not in F3/4 or F7/8.[@bib0019]Model of LST theoryln power density F4 − ln power density F360% trait - 40% state[@bib0018]Model of LST theoryln F4 − ln F340--50% state[@bib0036]Averaged over 13 asymmetry measures (from 13 homologous electrode pairs): Cronbach\'s alpha (0.87) and ICC (0.57)log F4 − log F3High to modest test-retest reliability[@bib0037]Test-retest correlationsF4 − F3Variation in outcome: low in general, but it is correlating. Test-retest correlations differ per research site, but is in general significant for F3-F4: 0.371 (see supplement).[@bib0038]1. t-tests of asymmetry measures. 2. ICCs and Pearson correlations. 3. Cronbach\'s alphaslog R minus log L power density1. Stable: \"...asymmetry measures tended to be associated with nonsignificant shifts in mean values over time\". 2. Not very high, buy significant ICCs (0.66 for Avg Ref baseline only, 0.79 for Avg Ref across time). 3. Acceptable-to-excellent Cronbach\'s alphas.[@bib0007]1. ANOVA on FAA, with hemisphere and group. 2. Correlation FAA-BDI.ln\[right\] − ln\[left\]Overall: doubtful, whether cross-sectional data is sufficient to establish trait properties. But there are no indications against FAA having trait properties. 1. No interaction especially between MDD and remitted, but also controls. 2. No correlation.[@bib0013]1. One-way ANOVAs on FAA between the HC, Mda- and rMDa- . 2. Correlation FAA-BDIln\[right ROI\] − ln\[left ROI\]The most relevant results: 1. No differences between MDD and remitted. 2. No correlations.[@bib0015]Regression with 1st predictor "Never vs. Ever depressed" and 2nd predictor "Currently depressed vs. remitted"log R − log LMost relevant results: No difference between currently depressed and remitted. FAA seems to be a state independent marker.[@bib0017]Correlation FAA-BDIln\[right\] − ln\[left\]Overall no specific conclusion on state or trait, but no correlations were found in the MDD group.[@bib0028]Correlation FAA-BDIright − leftOverall: \"\[our results\] highlight the trait like quality of reduced relative left frontal EEG activity.\" 1. No correlation.[^4]

Appendix B. Comparison baseline and week-8 data {#sec0016}
===============================================

To justify the use of a follow-up sample that is supposed to contain the same MDD patients as the baseline data (paragraph 3.5), but does not due to incomplete assessments, we performed the baseline analysis from [@bib0002] on only those who *did* have a complete week-8 assessment. The effect within the SSRI group was the same (*p* = .001, *F*(1,150) = 10.619, see [Table B1](#tbl0004){ref-type="table"} for all statistics).Table B1P-values of mentioned interaction effects in the re-analysis of [@bib0002] with data only of MDD patients who had measurements after 8 weeks (thus excluding FAA baseline measurements of patients who did not return for follow-up).Table B1Original analysisOriginal analysis without patients with no follow-up*Re*-analysis with week-8 FAA\*Females SSRI: Response*P* = .001*P* = .001*P* = .028Females venlafaxine: Response*P* = .070*P* = .011*P* = .821

Appendix C {#sec0017}
==========

[Table C1](#tbl0005){ref-type="table"}.Table C1Statistics paragraph 3.3. A: Severely depressed ≥53 years old only. B: Whole dataset.Table C1Sex(Interaction) EffectF (df)p (F)rp (r)AFemalesFAA Change2.080 (1,14).171FAA Change \* Treatment arm2.425 (2,14).125MalesFAA Change0.092 (1,7).771FAA Change \* Treatment arm0.061 (2,7).941FemalesFAA Change \* HRSD~17~ Change0.259.316MalesFAA Change \* HRSD~17~ Change−0.070.849BFemalesFAA Change0.355 (1,235).552FAA Change \* Treatment arm0.714 (2,235).491FAA Change \* Age0.889 (1,235).344FAA Change \* Depression severity0.645 (1,235).423FAA Change \* Treatment arm \* Age0.849 (2,235).429FAA Change \* Treatment arm \* Depression severity0.846 (2,235).430FAA Change \* Age \* Depression severity1.254 (1,235).264FAA Change \* Treatment arm \* Age \* Depression severity1.148 (2,235).319MalesFAA Change0.029 (1,194).864FAA Change \* Treatment arm0.282 (2,194).755FAA Change \* Age0.024 (1,194).878FAA Change \* Depression severity0.022 (1,194).881FAA Change \* Treatment arm \* Age0.292 (2,194).747FAA Change \* Treatment arm \* Depression severity0.471 (2,194).625FAA Change \* Age \* Depression severity0.052 (1,194).820FAA Change \* Treatment arm \* Age \* Depression severity0.352 (2,194).704

Appendix D. VQIDS-SR~5~ {#sec0018}
=======================

To control for AD side effects, we repeated analyses from paragraph 3.2 and 3.3 and replaced all HRSD~17~ variables with VQIDS-SR~5~ equivalents. Correlational analyses showed that FAA Change was neither significantly correlated to the change score in VQIDS-SR~5~ (*r* = 0.059, *p* = .225), nor to the percentage change in VQIDS-SR~5~ (*r* = 0.060, *p* = .219).

Focusing on variables known to have an influence on FAA, specifically in the subgroup we thought to be prone to changes in FAA (severely depressed females and males over 53 years old), we did not find the FAA Change score to be significantly correlated to the change score in VQIDS-SR~5~, although subsample sizes were small. Extending the Repeated Measures model from paragraph 3.2 showed that VQIDS-SR~5~ baseline severity and age are not significantly contributing to FAA Change, both in males and females (see [table D1](#tbl0006){ref-type="table"} for all statistics).Table D1VQIDS-SR~5~ Statistics paragraph 3.3. A: Severely depressed ≥53 years old only. B: Whole dataset.Table D1Sex(Interaction) EffectF (df)p (F)rp (r)AFemalesFAA Change \* VQIDS Change−0.121.644MalesFAA Change \* VQIDS Change0.127.381BFemalesFAA Change0.530 (1,225).467FAA Change \* Treatment arm0.002 (2,225).998FAA Change \* Age0.930 (1,225).336FAA Change \* VQIDS Depression severity0.125 (1,225).724FAA Change \* Treatment arm \* Age0.066 (2,225).936FAA Change \* Treatment arm \* VQIDS Depression severity0.145 (2,225).865FAA Change \* Age \* VQIDS Depression severity0.384 (1,225).536FAA Change \* Treatment arm \* Age \* VQIDS Depression severity0.351 (2,225).705MalesFAA Change0.991 (1,225).321FAA Change \* Treatment arm1.491 (2,225).228FAA Change \* Age0.407 (1,225).524FAA Change \* VQIDS Depression severity1.214 (1,225).272FAA Change \* Treatment arm \* Age0.773 (2,225).463FAA Change \* Treatment arm \* VQIDS Depression severity1.739 (2,225).179FAA Change \* Age \* VQIDS Depression severity0.654 (1,225).420FAA Change \* Treatment arm \* Age \* VQIDS Depression severity1.158 (2,225).316

Appendix E {#sec0019}
==========

[Table E1](#tbl0007){ref-type="table"}.Table E1FAA means of the different subgroups reported in paragraph 3.5. Split on sex, medication type, EEG condition, response group, and time of assessment.Table E1BaselineWeek 8SexMedication typeEEG condition\*ResponseNon-responseResponseNon-responseFemaleSSRIEC0.019−0.0480.009−0.022EO0.009−0.0360.033−0.008SNRIEC0.0000.0280.010−0.004EO−0.0130.0250.0200.018MaleSSRIEC0.0030.0170.0130.030EO0.0150.0360.0440.036SNRIEC−0.015−0.028−0.031−0.023EO−0.010−0.045−0.0360.002[^5]

Appendix F. Bayesian Repeated Measures ANOVA and correlations {#sec0020}
=============================================================

F1. Elaborated Bayesian analyses paragraph 3.2 {#sec0021}
----------------------------------------------

Results of Bayesian testing of an absence of change in FAA, revealed a Bayes factor indicating evidence for the null hypothesis: the models with the factors FAA Change and Treatment Arm showed that the data occur \>7.4 times more likely under the null hypothesis, than under any alternative model with (a combination of) the factors. This means that moderate evidence for the null hypothesis was found with only FAA Change in the model (BF~01~ = 7.483), increasing to (very) strong evidence when adding a combination of the two main effects (BF~01~ = 240.356) and including their interaction effect (BF~01~ = 5109.119). The error percentage was \<2.5%, which indicates sufficient stability of the numerical algorithm that was used to obtain the result. For each factor, the BF~inclusion~ reflects how well the factor predicts the data by comparing the performance of all models that include the factor to the performance of all the models that do not include the factor. For both the factors FAA Change and Treatment Arm, there is weak evidence in favor of their inclusion (BF~inclusion~ = 0.134 and 0.031 respectively), as well as a weak evidence in favor of the inclusion of the interaction effect (BF~inclusion~ = 0.047). This implies that these factors are not providing evidence for change in FAA. See [Table F1](#tbl0008){ref-type="table"} for all results.Table F1Bayesian Repeated Measures ANOVA main analysis.Table F1Model comparisonModelsP(M)P(M\|data)BF~M~BF~01~error%Null model (incl. subject).200.85623.7491.000FAA Change.200.1140.5177.4831.276Treatment.200.0260.10732.8530.604FAA Change + Treatment.200.0040.014240.3562.282FAA Change + Treatment + FAA Change \*Treatment.2001.675e-46.702e-45109.1192.471[^6]Table F1Continued. Bayesian Repeated Measures ANOVA main analysis.Table F1Analyses of effectsEffectsP(incl)P(incl\|data)BF~Inclusion~FAA Change.400.1180.134Treatment.400.0300.031FAA Change \*Treatment.2001.675e-40.047[^7]

Bayesian Pearson correlations between FAA Change and the difference score HRSD~17~/the percentage difference HRSD~17~ reveal moderate to strong results, where the data are respectively 12.1 and 9.3 times more likely to occur under the null hypothesis than under the model assuming there is a correlation between the variables. See [table F2](#tbl0009){ref-type="table"} for all results.Table F2Bayesian Pearson correlations FAA Change vs. HRSD~17~ Change/HRSD~17~% Change.Table F2rBF~01~FAA Change--HRSD~17~ Change0.03912.111FAA Change--HRSD~17~% Change0.0529.275

F2. Elaborated Bayesian analyses paragraph 3.3 {#sec0022}
----------------------------------------------

Bayesian Repeated Measures ANOVAs for the two sex groups of severely depressed over the age of 53 reveal anecdotal (i.e. worth no more than a bare mention, a customary description for BFs ranging 1--3) to moderate results. Males: BF~01~ = 1.351--2.715 for models with only main effects, BF~01~ = 6.195 for the model with the interaction; BF~inclusion~ = 0.438--0.748; error% = 0.701--2.327. Females: BF~01~ = 1.864--2.944 for most models, BF~01~ = 4.304 for the model with only main effects of FAA Change and Treatment Arm; BF~inclusion~ = 0.434--1.462; error% = 0.922--1.372. Most models therefore provided no conclusive evidence for either the null or the alternative hypotheses, and BF~inclusion~s indicate that there is (very) weak evidence in favor of including the factors. However, some models indicated moderate evidence of the data being more likely to occur under the null hypothesis. See [Tables F3](#tbl0010){ref-type="table"} and [F4](#tbl0011){ref-type="table"} for all results.Table F3Bayesian Repeated Measures ANOVA for severely depressed males ≥53 years old.Table F3Model comparisonModelsP(M)P(M\|data)BF~M~BF~01~error%Null model (incl. subject).200.3632.2821.000FAA Change.200.1750.8512.0700.701Treatment.200.2691.4721.3510.687FAA Change + Treatment.200.1340.6182.7151.744FAA Change + Treatment + Time\*Treatment.200.0590.2496.1952.327[^8]Table F3Continued. Bayesian Repeated Measures ANOVA for severely depressed males ≥53 years old.Table F3Analyses of effectsEffectsP(incl)P(incl\|data)BF~Inclusion~FAA Change.400.3090.489Treatment.400.4030.748FAA Change \*Treatment.200.0590.438[^9]Table F4Bayesian Repeated Measures ANOVA for severely depressed females ≥53 years old.Table F4Model comparisonModelsP(M)P(M\|data)BF~M~BF~01~error%Null model (incl. subject).200.3932.5921.000FAA Change.200.2111.0691.8641.400Treatment.200.1710.8252.2990.528FAA Change + Treatment.200.0910.4024.3040.922FAA Change + Treatment + FAA Change \*Treatment.200.1340.6172.9441.372[^10]Table F4Continued. Bayesian Repeated Measures ANOVA for severely depressed females ≥53 years old.Table F4Analyses of effectsEffectsP(incl)P(incl\|data)BF~Inclusion~FAA Change.400.3020.536Treatment.400.2620.434FAA Change \*Treatment.200.1341.462[^11]

Bayesian Repeated Measures alternatives for the extended ANOVAs showed similar results to paragraph 3.2: for females, the data are ≥6.6 times more likely to occur under the null hypothesis than under the alternative hypothesis (only models including factor FAA Change: BF~inclusion~ FAA Change and FAA Change X Treatment Arm 0.152 and 0.102, error % ≤ 8.576), and ≥4.7 times more likely in case of males (only models including factor FAA Change: BF~inclusion~ Time and Time X Treatment Arm 0.132 and 0.151, error% ≤ 5.582). See [Tables F5](#tbl0012){ref-type="table"} and [F6](#tbl0013){ref-type="table"} for all results.Table F5Bayesian Repeated Measures ANOVA for females, with factors and covariates Treatment Arm, Age and Baseline HRSD17.Table F5Model comparisonModelsP(M)P(M\|data)BF~M~BF~01~error%Null model (incl. subject).050.54722.9831.000FAA Change.050.0831.7206.5961.069Age.050.0921.9355.9221.199FAA Change + Age.050.0140.26839.3771.598Baseline HRSD~17~.050.0972.0365.6571.928FAA Change + Baseline HRSD~17~.050.0150.28636.8581.939Age + Baseline HRSD~17~.050.0270.53420.0071.962FAA Change + Age + Baseline HRSD~17~.050.0040.077134.7582.073Treatment.050.0731.4907.5260.651FAA Change + Treatment.050.0110.21648.6531.854Age + Treatment.050.0130.24343.4381.488FAA Change + Age + Treatment.050.0020.039268.8594.110Baseline HRSD~17~ + Treatment.050.0130.25541.2591.331FAA Change + Baseline HRSD~17~ + Treatment.050.0020.040263.8041.689Age + Baseline HRSD~17~ + Treatment.050.0040.076137.6163.325FAA Change + Age + Baseline HRSD~17~ + Treatment.0505.979e-40.011915.6591.734FAA Change + Treatment + FAA Change\*Treatment.050.0010.022472.0715.124FAA Change + Age + Treatment + FAA Change\*Treatment.0501.915e-40.0042858.2252.712FAA Change + Baseline HRSD~17~ + Treatment + FAA Change\*Treatment.0502.204e-40.0042483.7728.576FAA Change + Age + Baseline HRSD~17~ + Treatment + FAA Change\*Treatment.0505.817e-50.0019410.1292.373[^12]Table F5Continued. Bayesian Repeated Measures ANOVA for females, with factors and covariates Treatment Arm, Age and Baseline HRSD17.Table F5Analyses of effectsEffectsP(incl)P(incl\|data)BF~Inclusion~FAA Change.4000.1320.152Age.5000.1570.187Baseline HRSD~17~.5000.1630.195Treatment.4000.1190.135FAA Change \*Treatment.2000.0020.102[^13]Table F6Bayesian Repeated Measures ANOVA for males, with factors and covariates Treatment Arm, Age and Baseline HRSD17.Table F6Model comparisonModelsP(M)P(M\|data)BF~M~BF~01~error%Null model (incl. subject).050.1894.4161.000FAA Change.050.0250.4927.4713.978Treatment.050.3038.2620.6220.600FAA Change + Treatment.050.0400.7874.7401.459FAA Change + Treatment + FAA Change\*Treatment.050.0060.11830.6142.419Age.050.0470.9294.0451.842FAA Change + Age.050.0060.11132.3501.464Treatment + Age.050.0601.2033.1661.480FAA Change + Treatment + Age.050.0080.15223.8092.818FAA Change + Treatment + Age + FAA Change\*Treatment.050.0010.022162.9292.264Baseline HRSD~17~.050.0811.6842.3162.516FAA Change + Baseline HRSD~17~.050.0100.20118.0481.736Treatment + Baseline HRSD~17~.050.1302.8321.4541.023FAA Change + Treatment + Baseline HRSD~17~.050.0180.33910.7432.659FAA Change + Treatment + Baseline HRSD~17~ + FAA Change\*Treatment.050.0030.04973.4442.043Age + Baseline HRSD~17~.050.0280.5476.7401.240FAA Change + Age + Baseline HRSD~17~.050.0040.07051.1412.066Treatment + Age + Baseline HRSD~17~.050.0370.7285.1131.253FAA Change + Treatment + Age + Baseline HRSD~17~.050.0050.09737.0615.852FAA Change + Treatment + Age + Baseline HRSD~17~ + FAA Change\*Treatment.0507.334e-40.014257.1482.230[^14]Table F6Continued. Bayesian Repeated Measures ANOVA for males, with factors and covariates Treatment Arm, Age and Baseline HRSD17.Table F6Analyses of effectsEffectsP(incl)P(incl\|data)BF~Inclusion~FAA Change.400.1160.132Treatment.400.6001.538Age.500.1950.243Baseline HRSD~17~.500.3160.462FAA Change \*Treatment.200.0110.151[^15]

Appendix G: Male data equivalent to figure 2 with female data {#sec0018a}
=============================================================

Fig GMean values of male frontal alpha asymmetry (FAA, eyes open and eyes closed \[EO and EC\]), for the SSRI and venlafaxine groups, split up for responders and non-responders.Fig G

[^1]: MDD = major depressive disorder, HC = healthy controls, Ax. = assessment(s).

[^2]: Type 1: Multiple assessment moments with depressed patients. Type 2: Multiple assessment moments, only healthy controls. Type 3: Cross-sectional study.

[^3]: No explicit statements on state or trait were made by the authors (on electrode F3/F4 or F7/F8 based FAA), based on other literature we suggest our own conclusion to these results.

[^4]: \*Type 1: Multiple assessment moments with depressed patients. Type 2: Multiple assessment moments, only healthy controls. Type 3: Cross-sectional study. MDD = major depressive disorder, HC = healthy controls, Ax. = assessment(s), HRSD = Hamilton Rating Scale for Depression, CGI = Clinical Global Impression, BDI = Beck Depression Inventory, IDS-SR = Inventory of Depressive Symptomatology-Self Report, BIS/BAS = Behavioral Avoidance/Inhibition Scales, PANAS = Positive and Negative Affect Scale, ICC = Intraclass Correlation Coefficient, HRSD = Hamilton Rating Scale for Depression, HC = healthy controls, BDI = Beck Depression Inventory, LST theory = latent state-trait theory, Avg Ref = average reference.

[^5]: \*EC = eyes closed, EO = eyes open.

[^6]: Note: All models include subject.

[^7]: Note: Compares models that contain the effect to equivalent models stripped of the effect. Higher-order interactions are excluded.

[^8]: Note: All models include subject.

[^9]: Note: Compares models that contain the effect to equivalent models stripped of the effect. Higher-order interactions are excluded.

[^10]: Note: All models include subject.

[^11]: Note: Compares models that contain the effect to equivalent models stripped of the effect. Higher-order interactions are excluded.

[^12]: Note: All models include subject.

[^13]: Note: Compares models that contain the effect to equivalent models stripped of the effect. Higher-order interactions are excluded.

[^14]: Note: All models include subject.

[^15]: Note: Compares models that contain the effect to equivalent models stripped of the effect. Higher-order interactions are excluded.
